{
    "clinical_study": {
        "@rank": "109496", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Evaluate the long-term safety and tolerance of a synthetic formulation of\n      dehydroepiandrosterone, GL701, in patients with systemic lupus erythematosus who have\n      completed a prior GL701 protocol."
        }, 
        "brief_title": "Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus", 
        "condition": "Systemic Lupus Erythematosus", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive daily oral dehydroepiandrosterone for 12 months.  The\n      dose is adjusted based on disease activity and tolerance of treatment.\n\n      Patients are followed every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Systemic lupus erythematosus by American College of\n        Rheumatology criteria Mild to moderate disease characterized as follows: Prednisone dose\n        (or equivalent) 10 to 30 mg/day No daily dose 1 mg/kg or greater No alternate-day regimen\n        Failed prednisone taper in last 12 months and dose stable for at least 6 weeks prior to\n        entry OR No attempt to taper in last 12 months and dose stable for at least 3 months prior\n        to entry Prior completion of dehydroepiandrosterone (DHEA) study required No prior\n        participation in double-blind DHEA study at Stanford University --Prior/Concurrent\n        Therapy-- No concurrent immunosuppressants No concurrent participation in other clinical\n        studies No investigational agents within the longer of 30 days or 10 half-lives of the\n        agent At least 3 months since immunosuppressants, including: Adrenocorticotropin hormone\n        Androgens Cyclophosphamide Azathioprine Intravenous immune globulin At least 1 month since\n        change in dose of nonsteroidal anti-inflammatory drugs or hydroxychloroquine --Patient\n        Characteristics-- Age: 18 and over Sex: Female only Performance status: Not specified\n        Other: No hypersensitivity to DHEA or inactive ingredient in GL701 formulation, i.e.,\n        cornstarch, lactose, or magnesium stearate No condition that would prevent adequate\n        compliance with study No history of breast cancer or reproductive tract malignancy\n        Negative pregnancy test required within 2 weeks prior to entry Reliable contraception\n        required of fertile women No estrogen-containing oral contraceptive"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "20", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004665", 
            "org_study_id": "199/11935", 
            "secondary_id": "NU-552"
        }, 
        "intervention": {
            "intervention_name": "dehydroepiandrosterone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dehydroepiandrosterone"
        }, 
        "keyword": [
            "arthritis & connective tissue diseases", 
            "immunologic disorders and infectious disorders", 
            "rare disease", 
            "systemic lupus erythematosus"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Northwestern University", 
            "last_name": "Rosalind Ramsey-Goldman", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004665"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "June 1995", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}